The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
133 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $26,381,056 in first-year total cost, median $201,459.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-V (M2)]8
- Special Emphasis Panel[ZCA1 SRB-1 (M2)]7
- Special Emphasis Panel[ZCA1 SRB-P (M2)]7
- Special Emphasis Panel[ZCA1 TCRB-J (J1)]7
- Special Emphasis Panel[ZCA1 SRB-A (O1)]6
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR8
- JOHNS HOPKINS UNIVERSITY4
- SLOAN-KETTERING INST CAN RESEARCH4
- BAYLOR COLLEGE OF MEDICINE3
- DANA-FARBER CANCER INST3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Deciphering the metagenome-encoded pathway and domain structure for Palmerolide biosynthesis1R21CA205932-01A1 | BAKER, BILL JCHAIN, PATRICK S. G.MURRAY, ALISON ELIZABETH | DESERT RESEARCH INSTITUTE, NV | $325,324 | ZCA1 |
| 2018 | The role germline polymorphisms on ALL susceptibility1R21CA229922-01 | DUPUY, ADAM J. | UNIVERSITY OF IOWA, IA | $265,350 | ZCA1 |
| 2018 | Identifying novel regulatory activities on the surface of protein kinases1R21CA223347-01 | LUNDBLAD, VICTORIA | SALK INSTITUTE FOR BIOLOGICAL STUDIES, CA | $251,082 | ZCA1 |
| 2018 | Validation of Siglec-6 as a novel target for cancer immunotherapy1R21CA229961-01 | MUTHUSAMY, NATARAJANRADER, CHRISTOPH | SCRIPPS FLORIDA, FL | $246,464 | ZCA1 |
| 2018 | Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment1R21CA223367-01 | HAHN, MARIAYIM, JOHN H | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $242,633 | ZCA1 |
| 2018 | Identification of genomic drivers of brain metastases in renal cell carcinoma1R21CA220253-01A1 | BRASTIANOS, PRISCILLA KALIOPICARTER, SCOTTCHOUEIRI, TONI | MASSACHUSETTS GENERAL HOSPITAL, MA | $239,041 | ZCA1 |
| 2018 | Rpl22-Like1 as a Novel Prognostic Marker in Colorectal Cancer1R21CA216825-01A1 | WIEST, DAVID L. | RESEARCH INST OF FOX CHASE CAN CTR, PA | $238,815 | ZCA1 |
| 2018 | Development of molecular probes to investigate and drug the oncogenic Wnt/?-catenin/BCL9/B9L transcriptional complex1R21CA221683-01 | CARRASCO, RUBEN D | DANA-FARBER CANCER INST, MA | $229,576 | ZCA1 |
| 2018 | Identification of Plasma- and Exosome-Based Protein Biomarkers for Early Detection of Pancreatic Cancer Using SOMAscan Technology1R21CA218960-01A1 | LIBERMANN, TOWIA A. | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $228,375 | ZCA1 |
| 2018 | MALAT1 Depletion as a Therapeutic Strategy in Chronic Myelomonocytic Leukemia (CMML)1R21CA216757-01A1 | PADRON, ERIC | H. LEE MOFFITT CANCER CTR & RES INST, FL | $224,460 | ZCA1 |
| 2018 | Mechanisms of action of dual compound oncogenic PIK3CA mutations1R21CA223789-01A1 | SCALTRITI, MAURIZIO | SLOAN-KETTERING INST CAN RESEARCH, NY | $224,068 | ZCA1 |
| 2018 | Modulating the DNA methylation program through UHRF1 antagonism1R21CA216673-01A1 | FRYE, STEPHEN VERNONSTRAHL, BRIAN D | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $223,654 | ZCA1 |
| 2018 | Patient-Specific Mutation-Derived Tumor Neoantigens as Targets for Cancer Immunotherapy in Smoldering Multiple Myeloma1R21CA223953-01 | PAREKH, SAMIR | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $221,198 | ZCA1 |
| 2018 | Utility of RAS mimetics to block oncogenic signaling in colorectal cancer1R21CA227963-01 | REDDY, E PREMKUMAR | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $221,198 | ZCA1 |
| 2018 | Biomarkers of taxane chemotherapy response/resistance in prostate cancer1R21CA216800-01A1 | GIANNAKAKOU, PARASKEVI | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $221,198 | ZCA1 |
| 2018 | Targeting of TCF4 PARylation in the vascular niche to obliterate chemoresistant hepatocarcinoma cells1R21CA230098-01 | CAO, ZHONGWEI | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $221,198 | ZCA1 |
| 2018 | Image-Guided Drug Delivery and Treatment for GIST1R21CA223270-01 | CHOI, HAK SOO | MASSACHUSETTS GENERAL HOSPITAL, MA | $219,893 | ZCA1 |
| 2018 | Targeting chemoresistance in ovarian cancer1R21CA222425-01A1 | STORZ, PETER | MAYO CLINIC JACKSONVILLE, FL | $219,491 | ZCA1 |
| 2018 | A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cells1R21CA209298-01A1 | LI, SHAOGUANG | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $218,588 | ZCA1 |
| 2018 | Translational development studies of a novel combination therapy for castration-resistant prostate cancer1R21CA218774-01A1 | DENG, YIBINLU, JUNXUAN | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $214,380 | ZCA1 |
| 2018 | Imaging cell death in a preclinical rat model with metastatic osteosarcoma1R21CA229582-01 | GABRIELSON, KATHLEEN LOUISE | JOHNS HOPKINS UNIVERSITY, MD | $213,694 | ZCA1 |
| 2018 | Targeting Nodal/TGF-Beta pathway to inhibit invasion and growth of retinoblastoma1R21CA229919-01 | ASNAGHI, LAURAEBERHART, CHARLES G | JOHNS HOPKINS UNIVERSITY, MD | $213,694 | ZCA1 |
| 2018 | A pre-clinical x-ray/optical tomography-guided radiation research platform for pancreatic cancer1R21CA223403-01 | TRAN, PHUOC T.WANG, KEN KANG-HSIN | JOHNS HOPKINS UNIVERSITY, MD | $213,667 | ZCA1 |
| 2018 | Role of MTF1 in ovarian cancer1R21CA216585-01A1 | YUE, JUNMING | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $213,180 | ZCA1 |
| 2018 | A novel N-Ras pathway driving DCIS to basal-like breast cancer1R21CA226567-01 | CHANG, ERIC C | BAYLOR COLLEGE OF MEDICINE, TX | $212,055 | ZCA1 |
| 2018 | Learning radiomic signatures to early predict response of rectal cancer patients to neoadjuvant chemoradiation therapy1R21CA223358-01 | FAN, YONG | UNIVERSITY OF PENNSYLVANIA, PA | $210,105 | ZCA1 |
| 2018 | Treating high grade intraepithelial lesions of the anus with photodynamic therapy1R21CA223366-01A1 | BEN-JOSEF, EDGARBUSCH, THERESA M | UNIVERSITY OF PENNSYLVANIA, PA | $210,105 | ZCA1 |
| 2018 | Preclinical safety and efficacy assessment of a novel PCNA inhibitor for prostate cancer therapy1R21CA223049-01 | DONG, ZHONGYUN | UNIVERSITY OF CINCINNATI, OH | $208,854 | ZCA1 |
| 2018 | Lipidomics-based biomarkers for risk of progression in early prostate cancer1R21CA223527-01 | DAVIS, JOHNTHOMPSON, TIMOTHY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2018 | Co-targeting PDAC tumor cells and the microenvironment to succeed in EGFR/ErbB2-targeted therapy1R21CA223102-01 | YU, DIHUA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2018 | Manual Therapy for Fibrosis-related Late Effect Dysphagia in Head and Neck Cancer Survivors: The MANTLE Trial1R21CA226200-01 | HUTCHESON, KATHERINE ARNOLD | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2018 | Collateral Deletions Expose Targetable Metabolic Vulnerabilities in the PTEN locus1R21CA226301-01 | MULLER, FLORIAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2018 | Identification and Targeting of Chemotherapy Refractory Small Cell Lung Cancer1R21CA226322-01 | DOWLATI, AFSHIN | CASE WESTERN RESERVE UNIVERSITY, OH | $208,800 | ZCA1 |
| 2018 | Biological and Functional Significance of Lymphoma-Associated Macrophages in the Pathophysiology of Mantle Cell Lymphoma1R21CA222438-01A1 | FORD, RICHARD J | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2018 | Co-operative roles for YAP1 and UCHL5 in cancer progression and therapy1R21CA231654-01 | RAI, KUNAL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2018 | Targeting the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer1R21CA229716-01 | KUFE, DONALD W. | DANA-FARBER CANCER INST, MA | $207,757 | ZCA1 |
| 2018 | Clonal Expansion of HTLV-1-Infected Cells and Adult T Cell Leukemia1R21CA216660-01A1 | GIAM, CHOU-ZEN | HENRY M. JACKSON FDN FOR THE ADV MIL/MED, MD | $205,591 | ZCA1 |
| 2018 | A novel target to overcome chemoresistance in breast cancer1R21CA223389-01 | RINCON, MERCEDES | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, VT | $203,580 | ZCA1 |
| 2018 | Targeting IL-33 to boost immunotherapy of cancer1R21CA216574-01A1 | LU, BINFENG | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $203,580 | ZCA1 |
| 2018 | Development of a novel antiangiogenic drug for colon cancer by targeting neuropeptide Y receptors1R21CA216763-01A1 | SARKAR, CHANDRANI | OHIO STATE UNIVERSITY, OH | $203,363 | ZCA1 |
| 2018 | Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection1R21CA216807-01A1 | AGOPIAN, VATCHE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $203,254 | ZCA1 |
| 2018 | Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer1R21CA218973-01A1 | BIRRER, MICHAEL | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $203,042 | ZCA1 |
| 2018 | Exploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant Melanoma1R21CA215910-01A1 | LO, ROGER S | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $202,819 | ZCA1 |
| 2018 | Explore Epithelial Mesenchymal Transition (EMT) in a Cooperative Model of Metastasis in Renal Cell Carcinoma1R21CA216770-01A1 | WU, LILY | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $202,819 | ZCA1 |
| 2018 | Selectively Targeting a PI3K subunit to overcome temozolomide resistance and treat recurrent glioblastoma1R21CA216768-01A1 | SHENG, ZHI | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $202,343 | ZCA1 |
| 2018 | Development of a CF10 Predictive Gene Signature in CRC Organoids.1R21CA218933-01A1 | GMEINER, WILLIAM H. | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $202,275 | ZCA1 |
| 2018 | PET imaging of the tumor microenvironment for cancer detection1R21CA219899-01A1 | WADAS, THADDEUS J. | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $202,275 | ZCA1 |
| 2018 | The abscopal effect of nanosecond electric pulse tumor ablation and its enhancement for metastatic breast cancer1R21CA229939-01 | GUO, SIQI | OLD DOMINION UNIVERSITY, VA | $202,275 | ZCA1 |
| 2018 | Systems biology dissection of the road to T cell exhaustion within the tumor microenvironment to identify novel targets for tumor immunotherapy1R21CA216616-01A1 | HILL, ANN B | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $200,970 | ZCA1 |
| 2018 | Determining how autophagy mediates resistance to cancer therapies1R21CA222455-01A1 | THOMAS, GEORGE VICTOR | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $200,970 | ZCA1 |
| 2018 | Exploiting chemoimmunotherapy strategies with genetically-engineered gd T cells1R21CA223300-01A1 | GOLDSMITH, KELLY CSPENCER, H TRENT | EMORY UNIVERSITY, GA | $200,637 | ZCA1 |
| 2018 | PSMA - Targeted Small-Molecule Drug Conjugates1R21CA223121-01A1 | BERKMAN, CLIFFORD | WASHINGTON STATE UNIVERSITY, WA | $199,665 | ZCA1 |
| 2018 | Novel molecular probes for imaging colorectal cancer1R21CA216657-01A1 | GRAY, BRIAN DAVIDLIU, ZHONGLIN | UNIVERSITY OF ARIZONA, AZ | $199,183 | ZCA1 |
| 2018 | Targeting Musashi-2 (MSI2) regulation of EGFR and HER2 in lung cancer1R21CA223394-01A1 | BOUMBER, YANIS | RESEARCH INST OF FOX CHASE CAN CTR, PA | $199,013 | ZCA1 |
| 2018 | AR-V7 Acetylation in Castration Resistant Prostate Cancer1R21CA223119-01A1 | LIU, WANGUO | LSU HEALTH SCIENCES CENTER, LA | $198,781 | ZCA1 |
| 2018 | An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Metastatic Breast Cancer1R21CA226489-01 | COHEN, ADAM LWELM, ALANA L | UNIVERSITY OF UTAH, UT | $198,686 | ZCA1 |
| 2018 | Identifying outcome mediators of calorie restriction mimetic use in renal cancer1R21CA223126-01 | NORIAN, LYSE A | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $193,793 | ZCA1 |
| 2018 | Novel ODC Inhibitor Phaseolotoxin in Neuroblastoma1R21CA216867-01A1 | BACHMANN, ANDRE S | MICHIGAN STATE UNIVERSITY, MI | $193,750 | ZCA1 |
| 2018 | Treatment of Acute Myeloid Leukemia with C2-Set Domain-Specific CD33 Antibodies1R21CA223409-01A1 | WALTER, ROLAND BRUNO | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $191,400 | ZCA1 |
| 2018 | Selective Androgen Receptor Modulators for the Treatment of Prostate Cancer1R21CA230138-01 | NELSON, PETER S | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $191,400 | ZCA1 |
| 2018 | Accurate Determination of Dose to Mobile Organs at Risk in Hypofractionated Ablative Radiotherapy for Locally Advanced Pancreatic Cancer1R21CA223304-01A1 | MAGERAS, GIKAS S | SLOAN-KETTERING INST CAN RESEARCH, NY | $189,706 | ZCA1 |
| 2018 | Molecular and Imaging Assessment of Fallopian Tube Health1R21CA229707-01 | BARTON, JENNIFER KEHLET | UNIVERSITY OF ARIZONA, AZ | $188,966 | ZCA1 |
| 2018 | Opportunities for targeted therapies generated by APOBEC3A activity in acute myeloid leukemia1R21CA230065-01 | WEITZMAN, MATTHEW D. | CHILDREN'S HOSP OF PHILADELPHIA, PA | $187,050 | ZCA1 |
| 2018 | Slow-cycling cells, therapy resistance and clinical implications in prostate cancer1R21CA218635-01A1 | TANG, DEAN G. | ROSWELL PARK CANCER INSTITUTE CORP, NY | $186,833 | ZCA1 |
| 2018 | Lymph liquid biopsy in cancer1R21CA230059-01 | GALANZHA, EKATERINA I. | UNIV OF ARKANSAS FOR MED SCIS, AR | $184,875 | ZCA1 |
| 2018 | Clinical Evaluation of an Implantable Lab-in-a-patient microdevice that measures in-situ response to therapies in advanced ovarian cancer1R21CA216796-01A1 | JONAS, OLIVER | BRIGHAM AND WOMEN'S HOSPITAL, MA | $183,736 | ZCA1 |
| 2018 | Immunomodulation by dietary protein restriction1R21CA221942-01A1 | PILI, ROBERTO | INDIANA UNIVERSITY INDIANAPOLIS, IN | $183,372 | ZCA1 |
| 2018 | Targeting the IL-6 - SPINK1 regulatory axis in ovarian clear cell carcinoma1R21CA226302-01 | RADISKY, EVETTE S | MAYO CLINIC JACKSONVILLE, FL | $183,322 | ZCA1 |
| 2018 | Targeting aberrant promoter DNA methylation for anticancer therapy1R21CA229727-01 | SHEN, LANLAN | BAYLOR COLLEGE OF MEDICINE, TX | $182,700 | ZCA1 |
| 2018 | Adipose stromal cell targeting: a new approach to breast cancer treatment1R21CA216745-01A1 | KOLONIN, MIKHAIL GUENO, NAOTO T. | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $182,479 | ZCA1 |
| 2018 | Exploiting the immune microenvironment for radiotargeted destruction of leptomeningeal metastases1R21CA223325-01A1 | MINEA, RADU | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $179,438 | ZCA1 |
| 2018 | A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers1R21CA226303-01 | HE, TONG-CHUAN | UNIVERSITY OF CHICAGO, IL | $176,175 | ZCA1 |
| 2018 | Type III Collagen as a suppressor of breast cancer progression and metastasis1R21CA216552-01A1 | VOLK, SUSAN W | UNIVERSITY OF PENNSYLVANIA, PA | $175,088 | ZCA1 |
| 2018 | Deployable Endoluminal Ultrasound Phased Array for Precision Treatment of Pancreatic Cancer1R21CA230120-01 | DIEDERICH, CHRIS JOHN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $174,091 | ZCA1 |
| 2018 | Targeted Inhibition in Triple Negative Breast Cancer1R21CA229930-01 | NASSAR, NICOLAS | CINCINNATI CHILDRENS HOSP MED CTR, OH | $172,913 | ZCA1 |
| 2018 | Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast Cancer1R21CA230088-01 | KESTER, MARKPRICE, RICHARD J. | UNIVERSITY OF VIRGINIA, VA | $171,520 | ZCA1 |
| 2018 | Understanding the one-two punch: biomarkers of clinical response to a novel compensatory drug combination for metastatic TNBC1R21CA229951-01 | RADOVICH, MILAN | INDIANA UNIVERSITY INDIANAPOLIS, IN | $171,281 | ZCA1 |
| 2018 | Targeted proteomics to aid in the management of patients with stage IA lung adeno1R21CA223335-01 | BORGIA, JEFFREY A. | RUSH UNIVERSITY MEDICAL CENTER, IL | $170,738 | ZCA1 |
| 2018 | DESI-MS detection of positive margins in kidney cancer1R21CA229933-01 | BROOKS, JAMES D.ZARE, RICHARD N | STANFORD UNIVERSITY, CA | $170,738 | ZCA1 |
| 2018 | Contrast Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer1R21CA218946-01A1 | LIU, JI-BINLOREN, DAVID E | THOMAS JEFFERSON UNIVERSITY, PA | $169,650 | ZCA1 |
| 2018 | Exploring potential biomarkers predictive of response to ATR and CHK1 inhibitors1R21CA226317-01 | ZHANG, JUNRAN | OHIO STATE UNIVERSITY, OH | $169,650 | ZCA1 |
| 2018 | OTUB1 as a Novel Therapeutic Target in Kidney Cancer by Deubiquitinating HIF2alpha1R21CA223675-01 | ZHANG, QING | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $169,106 | ZCA1 |
| 2018 | Therapeutic potential of neutrophil protease inhibitors in colon cancer1R21CA216685-01A1 | OH, YOUNGMAN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $168,563 | ZCA1 |
| 2018 | Genetically Modified Natural Killer Cells for Cancer Immunotherapy1R21CA216652-01A1 | MORIARITY, BRANDEN S | UNIVERSITY OF MINNESOTA, MN | $167,476 | ZCA1 |
| 2018 | NOVEL PAN-RALGEF INHIBITORS TO BLOCK PANCREATIC CANCER.1R21CA216722-01A1 | CLARK, GEOFFREY J. | UNIVERSITY OF LOUISVILLE, KY | $167,475 | ZCA1 |
| 2018 | Evaluation of IRAK4 As A Novel Therapeutic Target in Colorectal Cancer1R21CA223112-01 | LIM, KIAN H | WASHINGTON UNIVERSITY, MO | $165,844 | ZCA1 |
| 2018 | NCI Clinical and Translational Exploratory/ Developmental Studies1R21CA223371-01 | ZHENG, GUANGRONG | UNIVERSITY OF FLORIDA, FL | $165,844 | ZCA1 |
| 2018 | Investigation of a lectibody targeting tumor-associated oligomannose glycans1R21CA216447-01A1 | MATOBA, NOBUYUKI | UNIVERSITY OF LOUISVILLE, KY | $165,555 | ZCA1 |
| 2018 | Mastl, a novel therapeutic target in Colon Cancer1R21CA216746-01A1 | DHAWAN, PUNITA | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $165,391 | ZCA1 |
| 2018 | Identifying Therapeutic Vulnerabilities of c-MYC-driven Small Cell Lung Cancer1R21CA216504-01A1 | OLIVER, TRUDY GALE | UNIVERSITY OF UTAH, UT | $165,300 | ZCA1 |
| 2018 | New Strategy for Pancreatic Cancer Therapy1R21CA223429-01 | SOLHEIM, JOYCE C | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $165,210 | ZCA1 |
| 2018 | Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis1R21CA216780-01A1 | LEE, YUEH Z | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $164,065 | ZCA1 |
| 2018 | Targeting MCJ/DNAJC15 and the mitochondrial electron transport chain in acute myeloid leukemia1R21CA223439-01 | DEGREGORI, JAMES V | UNIVERSITY OF COLORADO DENVER, CO | $163,459 | ZCA1 |
| 2018 | Discovery of Novel Drug Targets for Breast Cancer1R21CA222763-01 | FENG, XU | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $161,494 | ZCA1 |
| 2018 | Discovering adenosine kinase inhibitor targets in human neuroblastoma1R21CA218764-01A1 | LAN, MICHAEL S | LSU HEALTH SCIENCES CENTER, LA | $158,775 | ZCA1 |
| 2018 | A Chemopreventive Strategy Based on Edible MicroRNAs Produced in Plants1R21CA223353-01 | VANCE, VICKI | UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA, SC | $156,514 | ZCA1 |
| 2018 | A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC1R21CA229927-01 | GUPTA, ROMIWAJAPEYEE, NARENDRA | YALE UNIVERSITY, CT | $103,485 | ZCA1 |
| 2018 | Analysis of T-cell antigen diversity by deep sequencing1R21CA226321-01 | HOLT, ROBERT ANDREW | BRITISH COLUMBIA CANCER AGENCY, BC | $29,235 | ZCA1 |
| 2017 | Discovery of Predictive Biomarkers for Cancer Therapies using Synthetic Lethality1R21CA218778-01 | SAMBUCETTI, LIDIA CSINHA, SUBARNA | SRI INTERNATIONAL, CA | $277,285 | ZCA1 |
| 2017 | Candidate Gene Resequencing of Germline Multiple Myeloma1R21CA209533-01A1 | JOSEPH, VIJAI | SLOAN-KETTERING INST CAN RESEARCH, NY | $256,165 | ZCA1 |
| 2017 | Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer1R21CA216678-01 | BRADLEY, LINDA MAC PHERSON | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $254,475 | ZCA1 |
| 2017 | Metabolomic Strategies to Identify Biomarkers of Chemoprevention in FAP Patients1R21CA217130-01 | NEKLASON, DEBORAH WOODSAMADDER, NILOY JEWEL | UNIVERSITY OF UTAH, UT | $232,227 | ZCA1 |
| 2017 | Imaging VEGFR-1 in early metastatic lesions1R21CA216761-01 | BACKER, JOSEPH MLEWIS, JASON S. | SLOAN-KETTERING INST CAN RESEARCH, NY | $229,436 | ZCA1 |
| 2017 | Applying Chemical Biology to Target Deubiquitinating Enzymes in Lung Cancer1R21CA218787-01 | HAURA, ERIC B. | H. LEE MOFFITT CANCER CTR & RES INST, FL | $224,460 | ZCA1 |
| 2017 | Assessing the role of the DNA repair landscape in immune checkpoint therapy1R21CA216595-01 | SWEASY, JOANN B. | YALE UNIVERSITY, CT | $218,588 | ZCA1 |
| 2017 | Integrative genomic biomarkers for predicting response to immunotherapy in melanoma patients1R21CA218950-01 | HALABAN, RUTH | YALE UNIVERSITY, CT | $218,588 | ZCA1 |
| 2017 | Methylome characterization of bronchial epithelial projenitor cells1R21CA209436-01A1 | SPIVACK, SIMON DVIJG, JAN | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC, NY | $216,172 | ZCA1 |
| 2017 | Prior-image-based CT reconstruction for low-dose lung cancer screening1R21CA219608-01 | STAYMAN, JOSEPH WEBSTER | JOHNS HOPKINS UNIVERSITY, MD | $213,368 | ZCA1 |
| 2017 | Inhibition of Stromal-Derived DKK3 to Enhance the Response of Pancreatic Cancer to Immunotherapy1R21CA218495-01 | HWANG, ROSA F. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $208,800 | ZCA1 |
| 2017 | Targeting VCAM1-a4b1 Signaling to Ameliorate Pulmonary Osteosarcoma Metastasis1R21CA218790-01 | HUANG, ALEX YEE-CHEN | CASE WESTERN RESERVE UNIVERSITY, OH | $208,637 | ZCA1 |
| 2017 | Proteomics of Metastatic and Non-Metastatic Uveal Melanoma1R21CA209500-01A1 | CRABB, JOHN W | CLEVELAND CLINIC LERNER COM-CWRU, OH | $206,843 | ZCA1 |
| 2017 | RANK PATHWAY AND MAMMOGRAPHIC DENSITY IN MID-LIFE WOMEN1R21CA216515-01 | TORIOLA, ADETUNJI T | WASHINGTON UNIVERSITY, MO | $204,466 | ZCA1 |
| 2017 | Integrative signaling to increase efficacy of targeted therapies for triple negative breast cancer1R21CA218498-01 | MERAJVER, SOFIA DIANASOELLNER, MATTHEW B | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $203,580 | ZCA1 |
| 2017 | In vivo anti-PD1 gene therapy1R21CA204036-01A1 | LIEBER, ANDRE MICHAEL | UNIVERSITY OF WASHINGTON, WA | $202,112 | ZCA1 |
| 2017 | Mammographic Density and Metabolic Genotyping for Predicting Cancer Prognosis1R21CA208938-01A1 | CHEN, JEON-HORSU, MIN-YING L. | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $201,623 | ZCA1 |
| 2017 | Mechanism-based approach to combine histone deacetylase inhibitors with PARP inhibitors for therapy in AML1R21CA208937-01A1 | RASSOOL, FEYRUZ VIRGILIA | UNIVERSITY OF MARYLAND BALTIMORE, MD | $201,459 | ZCA1 |
| 2017 | Selective inhibition of Notch1 and ERBB3 by novel neutralizing antibodies to treat melanoma1R21CA218504-01 | BEDOGNI, BARBARA | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $201,459 | ZCA1 |
| 2017 | Targeting DNA Base Excision Repair in Acute Myeloid Leukemias1R21CA216551-01 | LLOYD, R. STEPHEN | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $200,970 | ZCA1 |
| 2017 | Directing Cancer Immunotherapy with Real-Time ImmunoPET1R21CA216648-01 | VIOLA, NERISSA THERESEWEI, WEI-ZEN | WAYNE STATE UNIVERSITY, MI | $200,970 | ZCA1 |
| 2017 | Image-guided Dosimetry for Injectable Brachytherapy based on Elastin-like Polypeptide Nanoparticles1R21CA218940-01 | CAI, JINGYIN, FANG-FANG | DUKE UNIVERSITY, NC | $200,107 | ZCA1 |
| 2017 | Immunotherapeutic Approaches Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer1R21CA216553-01 | KUFE, DONALD W. | DANA-FARBER CANCER INST, MA | $199,501 | ZCA1 |
| 2017 | Novel model to study PDAC using normal human pancreatic tissue1R21CA218968-01 | WANG, PEI | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $199,013 | ZCA1 |
| 2017 | Development of personalized surgical algorithms for muscle-invasive bladder cancer patients1R21CA218976-01 | ABBOSH, PHILIP | RESEARCH INST OF FOX CHASE CAN CTR, PA | $199,013 | ZCA1 |
| 2017 | A germline variant that predicts and modulates the response of melanoma to immunotherapy1R21CA209309-01A1 | OSMAN, IMAN | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $198,103 | ZCA1 |
| 2017 | Improving the radiation therapeutic ratio by inhibiting proinflammatory cytokines1R21CA205660-01A1 | KIM, JAE HO | HENRY FORD HEALTH SYSTEM, MI | $195,859 | ZCA1 |
| 2017 | Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases1R21CA216756-01 | FORSYTH, PETER ALEXANDERSMALLEY, KEIRAN | H. LEE MOFFITT CANCER CTR & RES INST, FL | $187,050 | ZCA1 |
| 2017 | Sphingosine-1-phosphate receptor subtype 3 in oncogenic K-Ras mutant-driven lung adenocarcinoma1R21CA216650-01 | LEE, MENQ-JER | WAYNE STATE UNIVERSITY, MI | $179,988 | ZCA1 |
| 2017 | Understanding Uncertainties in Radiomics Studies1R21CA216572-01 | COURT, LAURENCE E | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $174,000 | ZCA1 |
| 2017 | Specific induction of lethal autophagy in triple-negative breast cancer cells1R21CA208475-01A1 | CONNELL, TERRY D. | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $173,456 | ZCA1 |
| 2017 | Targeting cell metabolism for preventing and treating metastatic colon cancer1R21CA216604-01 | JIN, SHENGKAN VICTOR | RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL, NJ | $172,913 | ZCA1 |
| 2017 | De facto Target of Histone Deacetylase Inhibitors1R21CA215591-01 | SUN, ZHENG | BAYLOR COLLEGE OF MEDICINE, TX | $172,369 | ZCA1 |
| 2017 | Engineering Machinery Molecules to Visualize and Actuate Immunotherapy1R21CA209629-01A1 | WANG, YINGXIAO | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $168,563 | ZCA1 |
| 2017 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Low Grade Glioma1R21CA218625-01 | CONKLIN, HEATHER M | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $156,165 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.